The role of hormonal treatment in prostate cancer.
作者： Stephan H. Flüchter , Ralf Weiser , Christoph Gamper
DOI: 10.1007/978-3-540-40901-4_13
关键词:
摘要: In 1941 Huggins and Hodges published for the first time favorable effects of surgical castration estrogen treatment on progression metastatic prostate cancer. However, this hormonal therapy is not without side effects. Since pioneering milestone in history cancer, a further tremendous innovation did take place. Today, due to intensive clinical, biochemical, nuclear-biological molecular- biological research, many hormone active variations are available. Besides traditional therapy, or chemical castration, maximal androgen blockade, nontraditional forms intermittent antiandrogens, 5-α-reductase inhibitors, their combinations, we discuss options toward creating an increased number effect-oriented offers options, guaranteeing longer more comfortable exhaustion individual period response probably survival. The prerequisite closer-than-ever monitoring by tumor marker early observation symptomatic changes.
springer.com
sci-hub.st 参考文章(134)
M. P. Wirth, O. W. Hakenberg, M. Fröhner, Therapie des lokal fortgeschrittenen Prostatakarzinoms Der Urologe. ,vol. 44, pp. 1295- 1302 ,(2005) , 10.1007/S00120-005-0927-0
Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Journal of Clinical Oncology. ,vol. 17, pp. 1155- ,(1999) , 10.1200/JCO.1999.17.4.1155
和彦 小川, What's going on 放射線 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. JAMA. 2004;292:821-7. PMID:15315996--放射線治療に6ヵ月のアンドロゲン抑制療法(AST)を追加することにより、臨床的に限局性の前立腺癌患者の生存率が改善することを無作為化比較試験で示した論文 Mebio oncology. ,vol. 2, pp. 103- 105 ,(2005)
M.A. Ferro, D. Gillatt, M.O. Symes, P.J.B. Smith, High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. Urology. ,vol. 34, pp. 134- 138 ,(1989) , 10.1016/0090-4295(89)90248-3
Brian Schmitt, Charles Bennett, Jerome Seidenfeld, David Samson, Timothy J Wilt, Maximal androgen blockade for advanced prostate cancer Cochrane Database of Systematic Reviews. ,(1999) , 10.1002/14651858.CD001526
V. Hasselblad, D. J. Samson, A. M. Bayoumi, K. Ziegler, C. Bennett, A. Garber, A. Brown, Timothy J Wilt, P. C. Albertson, M. Gere, N. Aronson, J. Seidenfeld, Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evidence Report/Technology Assessment No. 4. (Prepared by Blue Cross/Blue Shield Association Evidence-based Practice Center under Contract NO. 290-97-0015). AHCPR Publication # 99-EE0012. Rockville, Maryland: Agency for Health Care Policy and Researc. ,(1999)
Bagshaw Ma, Ray Gr, Cox Rs, Status of radiation treatment of prostate cancer at Stanford University. NCI monographs : a publication of the National Cancer Institute. ,vol. 7, pp. 47- 60 ,(1988)
Cor W. Kuil, Cor A. Berrevoets, Eppo Mulder, Ligand-induced Conformational Alterations of the Androgen Receptor Analyzed by Limited Trypsinization STUDIES ON THE MECHANISM OF ANTIANDROGEN ACTION Journal of Biological Chemistry. ,vol. 270, pp. 27569- 27576 ,(1995) , 10.1074/JBC.270.46.27569
Arnold L. Potosky, Kevin Knopf, Limin X. Clegg, Peter C. Albertsen, Janet L. Stanford, Ann S. Hamilton, Frank D. Gilliland, J. William Eley, Robert A. Stephenson, Richard M. Hoffman, Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. Journal of Clinical Oncology. ,vol. 19, pp. 3750- 3757 ,(2001) , 10.1200/JCO.2001.19.17.3750
Philip W. Kantoff, Susan Halabi, Mark Conaway, Joel Picus, Jeffrey Kirshner, Vera Hars, Donald Trump, Eric P. Winer, Nicholas J. Vogelzang, Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study Journal of Clinical Oncology. ,vol. 17, pp. 2506- 2513 ,(1999) , 10.1200/JCO.1999.17.8.2506